RT Journal Article
SR Electronic
T1 Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.14.24304260
DO 10.1101/2024.03.14.24304260
A1 Li, Runhao
A1 Liu, Saifei
A1 Yeo, Kenny
A1 Edwards, Suzanne
A1 Li, Man Ying
A1 Santos, Ryan
A1 Kianpour Rad, Sima
A1 Wu, Fangmeinuo
A1 Maddern, Guy
A1 Young, Joanne
A1 Tomita, Yoko
A1 Townsend, Amanda
A1 Fenix, Kevin
A1 Hauben, Ehud
A1 Price, Timothy
A1 Smith, Eric
YR 2024
UL http://medrxiv.org/content/early/2024/03/15/2024.03.14.24304260.abstract
AB Secreted Frizzled-Related Protein 5 (SFRP5) modulates Wnt signalling pathways, affecting diverse biological processes. We assessed the diagnostic and prognostic value of circulating SFRP5 (cSFRP5) in colorectal cancer (CRC). Plasma cSFRP5 concentrations were measured using ELISA in healthy donors (n=133), individuals diagnosed with CRC (n=449), colorectal polyps (n=85), and medical conditions in other organs including cancer, inflammation, and benign states (n=64). Patients with CRC, polyps, and other conditions showed higher cSFRP5 levels than healthy individuals (p<0.0001). Receiver operating characteristic curves comparing healthy donors with medical conditions, polyps, and CRC were 0.814 (p<0.0001), 0.763 (p<0.0001), and 0.762 (p<0.0001), respectively. In CRC, cSFRP5 correlated with patient age (p<0.0001), tumour stage (p<0.0001), and histological differentiation (p=0.0273). Levels peaked in stage II versus I (p<0.0001), III (p=0.0007), or IV (p<0.0001), and were higher in stage III versus I (p=0.0007) and IV (p=0.0054), with no difference between I and IV. Elevated cSFRP5 levels predicted longer overall survival in stage II-III CRC (univariate: HR 1.82, 95% CI 1.02-3.26, p=0.024; multivariable: HR 2.34, 95% CI 1.12-4.88, p=0.015). This study confirms elevated cSFRP5 levels in CRC and reveals a correlation between elevated cSFRP5 and overall survival in stage II-III disease.Novelty and Impact Our study unveils the clinical significance of circulating Secreted Frizzled-Related Protein 5 (cSFRP5) as a potential diagnostic and prognostic marker in colorectal cancer (CRC). Analysing plasma from 731 participants, we provide novel insights into cSFRP5, observing elevated levels in CRC compared to healthy controls, with the highest concentrations in stage II. Importantly, elevated cSFRP5 levels correlate with prolonged survival in stage II-III patients, suggesting a promising avenue for improving outcomes and reducing recurrence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by AusHealth (Grant number RES-SFRP-01). Author Runhao Li has received an International PhD scholarship from The University of Adelaide.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee of Central Adelaide Local Health Network gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.(AUROC)area under the receiver operating characteristic(cSFRP5)circulating SFRP5(CRC)colorectal cancer(CRD)cysteine-rich domain(ELISA)enzyme-linked immunosorbent assay(dMMR)mismatch repair deficiency(pMMR)mismatch repair proficient(NTR)netrin-like domain(SFRP5)secreted frizzled-related protein 5